Related references
Note: Only part of the references are listed.Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer
I. H. Park et al.
ANNALS OF ONCOLOGY (2009)
Treatment of metastatic breast cancer: looking towards the future
Surabhi Amar et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Preclinical efficacy spectrum and pharmacokinetics of ixabepilone
Francis Y. F. Lee et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Phase III Study of Gemcitabine Plus Docetaxel Compared With Capecitabine Plus Docetaxel for Anthracycline-Pretreated Patients With Metastatic Breast Cancer
Stephen Chan et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
Linda T. Vahdat et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies
Alessandra Fabi et al.
BREAST (2008)
Preclinical discovery of ixabepilone, a highly active antineoplastic agent
Francis Y. F. Lee et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Novel taxane formulations in the treatment of breast cancer: A thought leader discussion and consensus roundtable
Julie Gralow et al.
CLINICAL BREAST CANCER (2008)
Metastatic breast cancer: The treatment challenge
Stephen E. Jones
CLINICAL BREAST CANCER (2008)
Maintenance treatment in metastatic breast cancer
A. Sanchez-Munoz et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2008)
Epothilones in breast cancer: current status and future directions
Francesco Atzori et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2008)
Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment
Kathy S. Albain et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Clinical Development of Ixabepilone and Other Epothilones in Patients with Advanced Solid Tumors
Edgardo Rivera et al.
ONCOLOGIST (2008)
Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer
Giuseppe Cancello et al.
BREAST CANCER RESEARCH (2008)
Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes
Joanne L. Blum et al.
CLINICAL BREAST CANCER (2007)
Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment
Eva S. Thomas et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine
Edith A. Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer
E. A. Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Investigation of tumor biomarkers as response predictors in a monotherapy study with lapatinib (L) as a first line treatment in ErbB2 amplified women with breast cancer
H. L. Gomez et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Estimates of the cancer incidence and mortality in Europe in 2006
J. Ferlay et al.
ANNALS OF ONCOLOGY (2007)
Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes:: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial
Miguel Martin et al.
LANCET ONCOLOGY (2007)
European perspective on the costs and cost-effectiveness of cancer therapies
Michael F. Drummond et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
Charles E. Geyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Does reimbursement influence chemotherapy treatment for cancer patients?
M Jacobson et al.
HEALTH AFFAIRS (2006)
Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer
WJ Gradishar et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer
SE Jones et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer
KD Miller et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Extending survival with chemotherapy in metastatic breast cancer
J O'Shaughnessy
ONCOLOGIST (2005)
Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer
P Fumoleau et al.
EUROPEAN JOURNAL OF CANCER (2004)
Assessment of the current Medicare reimbursement system for breast cancer operations
A Lucci et al.
ANNALS OF SURGICAL ONCOLOGY (2004)
Is breast cancer survival improving? Trends in survival for patients with recurrent breast cancer diagnosed from 1974 through 2000
SH Giordano et al.
CANCER (2004)
Prognostic and predictive factors in early-stage breast cancer
M Cianfrocca et al.
ONCOLOGIST (2004)
Facts and controversies in systemic treatment of metastatic breast cancer
C Bernard-Marty et al.
ONCOLOGIST (2004)
Multicenter phase II study of oral capecitabine (Xeloda®) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy
P Reichardt et al.
ANNALS OF ONCOLOGY (2003)
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women - A prospective combined analysis of two multicenter trials
JFR Robertson et al.
CANCER (2003)
Goals and objectives in the management of metastatic breast cancer
CT Chung et al.
ONCOLOGIST (2003)
Vinorelbine and cisplatin for metastatic breast cancer: A salvage regimen in patients progressing after docetaxel and anthracycline treatment
M Vassilomanolakis et al.
CANCER INVESTIGATION (2003)
Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure
J Bonneterre et al.
BRITISH JOURNAL OF CANCER (2002)
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results
J O'Shaughnessy et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Vinorelbine and cisplatin in metastatic breast cancer patients previously treated with anthracyclines
M Vassilomanolakis et al.
ANNALS OF ONCOLOGY (2000)